16 research outputs found
A control strategy to investigate the relationship between specific productivity and high-mannose glycoforms in CHO cells
Evaluating the Efficacy of Biosimilar Infliximab with the ACR50 Response in Patients with Rheumatoid Arthritis; A Meta-Analysis in Bayesian Framework
Budget Impact Analysis of Biosimilar Infliximab Treatment for Rheumatoid Arthritis in Six Central European Countries
PMH35 EQ-5D Utilities and Productivity of Adults With Attention-Deficit/Hyperactivity Disorder: Review of the Literature and a Cross-Sectional Survey in Hungary
PND60 Non-Diabetic Peripheral Neuropathic Pain is Underdiagnosed in GP Practices Although it has High Impact on Patients' Health Related Quality of Life
Health related quality of life and disease burden of patients with cystic fibrosis and their caregivers: Results of the European BURQOL-RD survey in Hungary,Cystás fi brosissal élõ betegek és gondozóik életminõsége és betegségterhei: A BURQOL-RD európai felmérés magyarországi eredményei
Introduction: Data on disease burden of cystic fibrosis in Hungary are scarce. Aim: To assess quality of life and resource utilisations of patients with cystic fibrosis. Method: In a cross-sectional survey (BURQOL-RD project), the EQ-5D-5L questionnaire was applied and healthcare utilisations were retrospectively surveyed. Results: 110 patients participated in the study (age-groups, year: 0–13, N = 48; 14–17, N = 12; ≥18, N = 50), median age at the diagnosis was 1 year. EQ-5D-5L score in age-groups 18–24 and 25–34 was significantly lower than in the general population (p<0.05). 75 patients (68%) attended pulmonology care, 55 patients (50%) were hospitalised in the past 6 and 12 months, respectively, and 57 patients (52%) were taking dornase alpha. Five adult patients (10%) received help from non-professional caregiver. Conclusions: Cystic fibrosis leads to significant deterioration of quality of life. This study is the first from the Central Eastern European region that provides basic inputs for further health economic evaluations of cystic fibrosis care. Orv. Hetil., 2014, 155(42), 1673–1684.</jats:p